Acylhydrazone derivatives LASSBio-743 and 752 demonstrate oral antithrombotic efficacy in preclinical testing, suggesting potential as future cardiovascular therapeutics.
Hypothesis-generating in animals; human trials needed before considering clinical antithrombotic use.
All compounds were administered orally and have shown effective antithrombotic action independently of the thrombotic stimulus. These results indicate that compounds LASSBio-743 and 752 are potential candidates for the treatment of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Frattani et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: